August 17, 2026
Tychique T. Wasolua, Morgan S. Hardy, Tanner J. Bommersbach et al.
INTRODUCTION: Approximately 30-40% of patients with major depressive disorder fail to respond to conventional antidepressants. Ketamine and esketamine are increasingly used, yet synthesized data on cumulative safety remain limited. This systematic review evaluated long-term safety of both agents. METHODS: MEDLINE, PsycINFO, Embase, and Cochrane Library were searched from inception through...
Annals of Middle Eastern Medicine
August 15, 2026
Abdulaziz Turki Alqabli, Aisha Abdullah Ateeq Alharbi, Wajan Majed Alahmadi et al.
Background: Adolescent major depressive disorder (MDD) is associated with substantial impairment, suicide risk, and limited response to standard treatments. Intravenous ketamine has rapid antidepressant effects in adults, but pediatric evidence remains limited. This systematic review and meta-analysis evaluated the short-term efficacy and safety of intravenous ketamine for adolescents with MDD,...
Journal of Affective Disorders
August 15, 2026
Michał Walaszek, Wiesław Jerzy Cubała, Zofia Kachlik et al.
Anhedonia, a core symptom of major depressive disorder (MDD), is associated with illness severity, suicide risk, poor functioning, and predicts poor response to antidepressants. While no treatments are approved, ketamine and esketamine show promise in reducing anhedonia. This study examines clinical and sociodemographic features linked to anhedonia treatment response in treatment-resistant...
medRxiv
August 14, 2026
Annette M Braxton, Christina Driver, Daniel F. Hermens et al.
preprint
Abstract Major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) are prevalent, chronic, and disabling mental health conditions which are difficult to treat. Ketamine has demonstrated effect for improving depression and PTSD symptoms independently but reports often overlook focused comorbid improvement of these symptoms within individuals. To address this, we assessed...
ACS Medicinal Chemistry Letters
August 13, 2026
Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel tetrahydropyridinyl-6,6-bicyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse and headaches, and processes for preparing such compounds.
Zenodo (CERN European Organization for Nuclear Research)
August 11, 2026
Saanvi Gutta
preprint
Depression affects over 280 million people worldwide and remains one of the leading causes of disability and suicide. Existing treatments such as SSRIs and traditional psychotherapy often fail to provide relief, especially for individuals with treatment‑resistant depression. Recent clinical trials suggest that psychedelic‑assisted therapy using psilocybin or MDMA may offer rapid and durable...
Frontiers in Physiology
August 10, 2026
Dan Yu, Ye Liao, Jie Li et al.
Propofol, one of the most widely used intravenous anesthetics, is undergoing a transformative identity shift from a purely surgical agent to a potential therapeutic tool for neuropsychiatric disorders. This review synthesizes current evidence on the emerging field of propofol therapeutics, with a focus on its rapid antidepressant, anti-anhedonia, and anxiolytic effects. We first examine...
Journal of Affective Disorders
August 10, 2026
Discordant signals: How outcome measurement shapes interpretation of ketamine response in treatment-resistant depression.
Journal of Affective Disorders
August 10, 2026
Yves Martins Varela, Patrícia Cavalcanti-Ribeiro, Geovan Menezes de Sousa et al.
BACKGROUND: Ketamine is an effective rapid-acting treatment for treatment-resistant depression (TRD), producing antidepressant effects within hours of administration. Because it induces states of heightened neuroplasticity and psychological openness, psychotherapy may enhance its therapeutic effects. METHODS: This exploratory, nonrandomized, open-label clinical trial evaluated the adjunctive...
The Journal for Nurse Practitioners
August 10, 2026
Tanner Herb, Heeyoung Lee, Prabir Mullick et al.
This quality improvement project examined the impact of shared decision-making–guided music intervention integrated into esketamine treatment on depressive symptoms and quality of life in 10 adults with treatment-resistant depression at a private psychiatric clinic. Over 4 months, patients collaborated with their providers to select and listen to music during each session. Depressive symptoms...